343P DPYD gene sequencing and in silico functionality prediction of polymorphisms in 3,471 colorectal cancer patients treated with fluoropyrimidine (FP)

M-C Etienne-Grimaldi,Y.A Wettergren,G Le Teuff,S.P Ackland,J Rousset,J-P Desvignes,J Taieb,E Menoret,M Schwab,V Boige,B Jennings,E Seutin,P Laurent-Puig,Y Koudou,C Béroud,N Cozic,J-C.C Boyer

doi:10.1016/j.annonc.2022.07.481

343P DPYD gene sequencing and in silico functionality prediction of polymorphisms in 3,471 colorectal cancer patients treated with fluoropyrimidine (FP)

M-C Etienne-Grimaldi, Y.A Wettergren + Show 15 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.481

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Centre Antoine Lacassagne, University of Gothenburg, Institut Gustave Roussy, University of Newcastle Australia, Aix-Marseille University, Universitätsklinikum Tübingen, University of East Anglia, Délégation Paris 5, Université Paris Cité, Centre Hospitalier Universitaire de Nîmes

#DPYD Gene #Dihydropyrimidine Dehydrogenase + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

FP pharmacodynamics potentially depends on polymorphisms of genes related to its catabolism, anabolism, folate pathways, targets and transporters. EMA, CPIC and DPWG recommend DPYD testing (consensual variants *2A/*13/D949V/HapB3 of the DPYD gene coding for dihydropyrimidine dehydrogenase (DPD)) before starting FP chemotherapy. The main objective of this study is to identify a multigenic signature improving current recommendation to identify patients at risk of severe FP-induced toxicities. We herein present genetic results of DPYD sequencing.

Full Text